(All fields required)
Please enter a valid email.
Please enter your name.
The overall goal
of Dr. Bucuvalas’s research efforts is to ensure the best possible
outcome for the population of pediatric liver transplant recipients by
acquisition and application of new discovery and by improvement of the
delivery system. Studies conducted in the lab are directly related to gaps in
knowledge for best outcomes for liver transplant recipients. These
patient-centered studies are multicenter efforts, derivative of the relatively
rarity of LTX and the need to work among clinical centers to achieve adequate
sample size to power the study. One of the efforts is focused on
detection of non-adherence, results of which are expected to have broad implications, beyond the specific field
of pediatric liver transplant recipients. A second effort is a Clinical Trial
of Immunosuppression Withdrawal for Stable Pediatric Liver Transplant
Recipients. The motivation to withdraw
pediatric liver tx recipients from immunosuppression a logical outgrowth of the recent studies
reporting the long-term mortality and morbidity in children who face heavy
cumulative burden of life-long immunosuppression. We
seek to identify that subset of pediatric liver transplant recipients who can
safely and durably withdraw from immunosuppression.
Dr. Bucuvalas is
recognized both locally with a Chair in Transplant Hepatology and
internationally as an expert in pediatric transplant hepatology and has served
as Chair of SPLIT, a multi-center consortium of pediatric liver transplant
programs in North America, and on the inaugural transplant hepatology committee
of the American Boards of Internal Medicine and Pediatrics. Dr. Bucuvalas has
published widely in transplant hepatology, is co-investigator on the senior
steering committee for 3 patient-based research studies funded by NIDDK and
NIAID, and currently serves on the Editorial Board for Hepatology and as an
Associate Editor for Clinical Liver Disease.
Alonso EM, Martz
K, Wang D, Yi MS, Neighbors K, Varni JW, Bucuvalas JC. Factors predicting health-related quality of life in pediatric liver transplant recipients in the functional outcomes group. Pediatr Transplant;17:605-11. 2013.
Grimley M, Bucuvalas J. Pediatric Acute Liver Failure and Immune Dysregulation. J Pediatr 2013.
Kirkendall E, Nguyen H, Schaffzin JK, Bucuvalas J, Bracke T, Seid M,
Ashby M, Foertmeyer N, Brunner L, Lesko A, Barclay C, Lannon C, Muething S.Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatrics; 132:e756-67. 2013.
Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, Olio DD,
Karpen S, Bucuvalas J, Lobritto S, Rand E, Rosenthal P, Horslen S, Ng V,
Subbarao G, Kerkar N, Rudnick D, Lopez MJ, Schwarz K, Romero R, Elisofon S, Doo
E, Robuck PR, Lawlor S, Belle SH. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology; 57:1542-9. 2013.
Bucuvalas J, Filipovich L, Yazigi N, Narkewicz MR, Ng V, Belle SH, Zhang S, Squires RH. Immunophenotype Predicts Outcome in Pediatric Acute Liver Failure. J Pediatr Gastroenterol Nutr; 56(3):311-315. Mar 2013.
Ng VL, Alonso EM, Bucuvalas JC, et al. Health Status of Children Alive 10 Years after Pediatric Liver Transplantation Performed in the US and Canada: Report of the Studies of Pediatric Liver Transplantation Experience. J Pediatr;160:820-6. 2012.
Squires, RH, Dhawan A, Alonso E, Narkewicz M, Shneider B, Rodriguez-Baez N, Dell Olio D, Karpen S, Bucuvalas J et al. Intravenous N-acetylcysteine in Pediatric Patients with Non-Acetaminophen Acute Liver Failure: A Placebo-Controlled Clinical Trial. Hepatology 2012 (IN PRESS)Englesbe RM , Kelly B, Goss J, Fecteau A, Mitchell J, Andrews W, Krapohl G, Magee J, Mazariegos G, Horslen S and Bucuvalas J. Reducing Pediatric Liver Transplant Complications: A Potential Roadmap for Transplant Quality Improvement Initiatives within North America. American Journal of Transplantation, 12:2301-2306. 2012.
Grippa, F., Gloor, P.A., Bucuvalas, J.C. and Palazzolo, M. Supporting development efforts of clinical care teams, Int. J. Organisational Design and Engineering, Vol. 2,No. 2, pp.149–166. 2012.
The Banff Working Group on Liver Allograft Pathology. Importance of Liver Biopsy Findings in Immunosuppression Management: Biopsy Monitoring and Working Criteria for patients with Operational Tolerance (OT). Liver Transplantation 2012 (IN PRESS).
Kamath, B; Yin W, Miller H, Anand R, Rand E, Alonso E, Bucuvalas J. The SPLIT Experience Outcomes of Liver Transplantation in Alagille Syndrome. Liver Transplantation ; 18:940-948. 2012.
Akimova T, Kamath B, Goebel J, Meyers K, Rand E, Hawkins A, Levine M, Bucuvalas J, Hancock W. Differing Effects of Rapamycin or Calcineurin Inhibitor on T-Regulatory Cells in Pediatric Liver and Kidney Transplant Recipients. Am Journal of Transplantation 2012 12-3449-3461.
L.G. Sorensen; K. Neighbors; K. Martz; F. Zelko, Bucuvalas JC, and Alonso EM. Intellectual and Academic Outcomes after Pediatric Liver Transplantation: Functional Outcomes Group. Am J Transpla. 2011
Ng VL, Alonso EM, Bucuvalas JC, et al. Health Status of Children Alive 10 Years after Pediatric Liver Transplantation Performed in the US and Canada: Report of the Studies of Pediatric Liver Transplantation Experience. J Pediatr 2011.nt. 2011 Feb ;11 (2):303-11
Alonso EM, Limbers CA, Neighbors K, Martz K, Bucuvalas JC, Webb T, and Varni JW. Cross-sectional Analysis of Health-Related Quality of Life in Pediatric Liver Transplant Recipients. J Pediatr;156:270-6. 2010
Campbell KM, Ng V, Magee J, Goebel J, Anand R, Martz K, and Bucuvalas J. Glomerular filtration rate following pediatric liver transplantation -- the SPLIT experience. Am J Transplant;10:2673-82. 2010
Limbers CA, Neighbors K, Martz K, et al. Health-related quality of life in pediatric liver transplant recipients compared with other chronic disease groups. Pediatr Transplant 2010.
Varni JW, Limbers CA, Sorensen LG, et al. Cognitive Functioning Scale in pediatric liver transplant recipients: feasibility, reliability, and validity. Qual Life Res PedsQL 2010.
John C. Bucuvalas M.D.
Integrated Solid Organ Transplant ProgramCincinnati Children's Hospital 3333 Burnet AvenueCincinnati, Ohio 45229Phone: 513-803-1791Fax: 513-636-7805
Andre HawkinsSenior Clinical Research CoordinatorCincinnati Children's Hospital 3333 Burnet AvenueCincinnati, Ohio 45229Phone: 513-636-7511Fax: 513-636-7805E-mail: email@example.com
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center